Skip to main content

Table 3 Key baseline laboratory data (treated set; n = 7034)

From: Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

HbA1c (%), mean (SD)

8.1 (0.8)

HbA1c <8.5%, n (%)

4811 (68)

Fasting plasma glucose (mmol/L), mean (SD)

8.5 (2.4)

Body mass index (kg/m2), mean (SD)

30.6 (5.3)

≥ 35 kg/m2, n (%)

1426 (20)

Weight (kg), mean (SD)

86.4 (18.9)

Waist circumference (cm), mean (SD)

105 (14)

Systolic/diastolic blood pressure (mmHg), mean (SD)

135 (17)/77 (10)

Lipids (mmol/L), mean (SD)

 

  Total cholesterol

4.2 (1.1)

  LDL-cholesterol

2.2 (0.9)

  HDL-cholesterol

1.2 (0.3)

  Triglycerides

1.9 (1.4)

eGFR according to MDRD (mL/min/1.73 m2), mean (SD)

74 (21)

eGFR according to MDRD (mL/min/1.73 m2), n (%)

 

  ≥90

1534 (22)

  60 to <90

3671 (52)

  30 to <60

1796 (26)

ACR albumin ratio (mg/g), median (Q1, Q3)

17.7 (7.1, 72.5)

ACR ratio (mg/g), n (%)

 

  ≥ 30 – 300

2011 (29)

  ≥ 300

771 (11)

  1. Results (based on a pre-final version of the database of this ongoing trial) may change slightly once trial is completed.